Synergistic combination therapy of lung cancer: Cetuximab functionalized nanostructured lipid carriers for the co-delivery of paclitaxel and 5-Demethylnobiletin

Shenghu Guo(Hebei Medical University), Yuehua Zhang(Fourth Hospital of Hebei Medical University), Zheng Wu(Fourth Hospital of Hebei Medical University), Lei Zhang(Hebei Medical University), Dongwei He(Hebei Medical University), Xing Li(Fourth Hospital of Hebei Medical University), Zhiyu Wang(Hebei Medical University)
Biomedicine & Pharmacotherapy
July 17, 2019
10.1016/j.biopha.2019.109225
Cited by 86Open Access
Full Text

Abstract

at the end of the study. The highest tumor accumulation amount and low toxicity made CET-PTX/DMN-NLCs a promising system for the synergistic combination therapy of lung cancer.

Related Papers

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors
Ting‐Chao Chou, Paul Talalay|Advances in Enzyme Regulation|1984|7.2k
Promotion of microtubule assembly in vitro by taxol
Peter B. Schiff, Jane Fant, Susan Band Horwitz|Nature|1979|3.6k
Lung Cancer Statistics
Lindsey A. Torre, Rebecca L. Siegel, Ahmedin Jemal|Advances in experimental medicine and biology|2015|2k
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
Christopher G. Azzoli, Sherman Baker, Sarah Temin et al.|Journal of Clinical Oncology|2009|913
Enhancing the Toxicity of Cancer Chemotherapeutics with Gold Nanorod Hyperthermia
Tanya S. Hauck, Travis L. Jennings, Tetyana Yatsenko et al.|Advanced Materials|2008|396